First-Generation TRK Inhibitors: Clinical Evidence and Indications

In this episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss key clinical data leading to FDA approvals and current indications for first-generation TRK inhibitors in NTRK fusion–positive solid tumors and ROS1-positive NSCLC. Topics include:Basket trials leading to FDA approvals of larotrectinib and entrectinibCurrent pan-tumor indications for first-generation TRK inhibitors in NTRK fusion–positive solid tumors as well as ROS1-positive NSCLCSequencing treatment with TRK inhibition in patients with solid tumorsClinically relevant similarities and differences between larotrectinib and entrectinibPresenters:George D. Demetri, MDProfessor of MedicineHarvard Medical SchoolHarvard UniversityCo-Director, Ludwig Center at HarvardSenior Vice President for Experimental TherapeuticsDirector, Sarcoma CenterDana-Farber Cancer InstituteBoston, MassachusettsAlexander Drilon, MDChief, Early Drug DevelopmentAttending, ThoracicMemorial Sloan Kettering Cancer CenterNew York, New YorkLink to full program, including downloadable slidesets:https://bit.ly/2YFIPfr

There are no comments yet.

Please log in to write the first comment.